DTIL Precision BioSciences, Inc.
Precision BioSciences, Inc. (DTIL) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.97 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +6.1% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
Sector
Healthcare
Industry
Biotechnology